Plasma viscosity

Plasma viscosity is a physical property of blood plasma resulting mainly from its protein content, especially high-molecular-weight proteins like fibrinogen and immunoglobulins[3][4][6]. It is measured in millipascal-seconds (mPa·s) or centipoise (cP), with normal values at 37°C ranging from approximately 1.10–1.30 mPa·s[3][4]. Plasma viscosity is a key determinant of blood rheology, influences microvascular resistance and tissue perfusion, and is considered a marker rather than a molecular drug target. It rises in many inflammatory, hematologic, and cardiovascular disorders, correlates with risk and severity of disease, and is used as a biomarker in a variety of clinical scenarios including hyperviscosity syndromes, cardiovascular diseases, and inflammatory conditions[3][4][8]. However, plasma viscosity itself is not a discrete molecule, receptor, enzyme, or classical therapeutic target[3][4][5]. Direct drug targeting of plasma viscosity is not recognized; interventions are indirect, e.g., plasma exchange. Key interpretive note: Plasma viscosity is not a molecule, receptor, enzyme, or protein, but a macroscopic physical parameter measurable in the laboratory. It describes the flow resistance of plasma, not a druggable biological entity. Thus, it is not appropriate to list under molecular targets, has no direct interacting drugs, and serves as a biomarker or pathophysiological indicator. Selecting "Plasma viscosity" as a therapeutic target is incorrect and should be flagged as such[3][4][5].

Other names

PV